J&J Submits sBLA To FDA for Guselkumab in Ulcerative Colitis

Individuals included in the study reported positive changes in fatigue, and disease activity displayed endoscopic and histologic remission.

Related Keywords

David Lee , Johnson , Biologics License Application , Global Therapeutic Area Head Immunology ,